OBJECTIVE: This study aimed to investigate the differences of results of Older Adult Behavior Checklist (OABCL) in subjects with dementia, mild cognitive impairment (MCI), and normal group. METHODS: The data was composed of 42 patients with MCI, 71 patients with dementia, and 111 randomly collected participants who were recruited for standardization of Korean version of Achenbach System of Empirically Based Assessment Older Adult Forms. Medical records, results of OABCL, neuropsychological tests, activities of daily living scale, and clinical dementia rating scale of the subjects were retrospectively analyzed to find significant factors in distinguishing the groups. RESULTS: In dementia group, almost of the empirically base problem scales and Diagnostic and Statistical Manual of Mental Disorders (DSM)-oriented scales showed significantly higher scores than MCI or normal groups. MCI group also showed higher scores in several empirically base problem and DSM-oriented scales than normal group. Also, functional impairment, memory/cognition, thought problems, irritable/disinhibited scales of empirically base problem and depressive, dementia, psychotic problems DSM-oriented scales significantly predict in distinguishing the three groups. CONCLUSION: The results implicated that OABCL is not only useful in assessing cognition decline but also in investigating psychological and behavioral problems of older adults.
Activities of Daily Living ; Adult* ; Checklist* ; Cognition ; Cognition Disorders* ; Dementia ; Diagnostic and Statistical Manual of Mental Disorders ; Humans ; Mass Screening* ; Medical Records ; Mild Cognitive Impairment ; Neuropsychological Tests ; Problem Behavior ; Psychopathology* ; Retrospective Studies ; Weights and Measures

Background: Need for regulatory science is emerging with the development of pharmaceutical industry. It is essential to train regulatory science experts to meet the needs of technology and regulations to evaluate advanced products. Major regulatory science countries are conducting the regulatory science activities and fostering the experts. Methods: Published literature and the relevant website of European Union (EU) were reviewed and criteria were developed. In particular, we focused on in depth descriptions of the Innovative Medicines Initiative program, which was conducted twice. Results: EU is striving to provide funding and training experts for the development of the regulatory science by horizon 2020 and regulatory science to 2025. Innovative medicines initiative (IMI) is a public-private partnership aimed at the development of the pharmaceutical industry, including the regulatory science. IMI education and training projects have provided various education and training course including short-term curriculum and master and doctoral course. The difference between South Korea’s regulatory science expert training project in 2021 and the EU’s IMI education and training projects is participation of pharmaceutical companies. While the pharmaceutical companies participate in the IMI project to select project topics and form a community, South Korea’s project is focused on the Ministry of Food and Drug Safety and universities. Conclusion Through successful active networks with regulatory party, pharmaceutical companies, and universities, a great innovative advance of regulatory science in South Korea is expected.

Background: Need for regulatory science is emerging with the development of pharmaceutical industry. It is essential to train regulatory science experts to meet the needs of technology and regulations to evaluate advanced products. Major regulatory science countries are conducting the regulatory science activities and fostering the experts. Methods: Published literature and the relevant website of European Union (EU) were reviewed and criteria were developed. In particular, we focused on in depth descriptions of the Innovative Medicines Initiative program, which was conducted twice. Results: EU is striving to provide funding and training experts for the development of the regulatory science by horizon 2020 and regulatory science to 2025. Innovative medicines initiative (IMI) is a public-private partnership aimed at the development of the pharmaceutical industry, including the regulatory science. IMI education and training projects have provided various education and training course including short-term curriculum and master and doctoral course. The difference between South Korea’s regulatory science expert training project in 2021 and the EU’s IMI education and training projects is participation of pharmaceutical companies. While the pharmaceutical companies participate in the IMI project to select project topics and form a community, South Korea’s project is focused on the Ministry of Food and Drug Safety and universities. Conclusion Through successful active networks with regulatory party, pharmaceutical companies, and universities, a great innovative advance of regulatory science in South Korea is expected.

Objective: This study aimed to develop a brief self-report measure of depressive and anxiety symptoms in victims of sexual violence. Methods: The sample, which consisted of 215 victims and 255 healthy controls, was recruited between December 2016 and November 2018 from eight Sunflower Centers. Eligible items were selected from existing scales of depression (CES-DC and CES-D) and anxiety (SAI-C and BAI) symptoms by item-total correlation coefficients and item response theory (IRT) analysis. Internal consistency coefficients were computed and the receiver operating characteristics curve was inspected to assess the validity of the brief scale and determine optimal cutoff scores. Results: The brief scales showed high internal consistency across all age groups. The optimal cutoff score of brief depression scale was 1.5 for children, 2.5 for adolescents, and 2.5 for the adults. That of brief anxiety scale was 8.5, 6.5, and 3.5, respectively. Conclusion The results underscore the need for age-appropriate screening measures of depressive and anxiety symptoms in victims of sexual violence.